Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study With Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial

NCT03864328 is registered in ClinicalTrials.gov with Respivant Sciences GmbH as lead sponsor.

NCT NCT03864328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03864328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study With Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial
Lead sponsor
Respivant Sciences GmbH
Phase
Phase 2
Overall status
Terminated
Start date
March 29, 2019
Completion date
June 5, 2020
Enrollment
108 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

chronic cough, ipf, persistent cough in ipf